This book provides an in-depth examination of the management of hepatocellular carcinoma (HCC) within the context of low to middle-income countries. It underscores the alarming fact that, by 2040, an estimated 1.3 million individuals are projected to succumb to liver cancer, representing a staggering 56.4% increase from figures recorded in 2020. Predictions indicate that both the incidence and mortality rates of HCC are anticipated to surge by over 50% within the next two decades.
The text thoroughly explores the complexities surrounding HCC management amid limited healthcare resources and budgets typical of low to middle-income countries. It discusses the varied costs associated with therapeutic options for HCC, including liver resection, transplantation, ablative therapies, transarterial embolotherapy/radiotherapy, systemic therapy, and palliative care, emphasizing the financial challenges faced in these settings.
Moreover, the book highlights the pivotal role of prevention strategies in mitigating the risk of HCC. It is intended for a diverse audience, including specialists in surgical oncology, medical oncology, radiation oncology, hepatology, gastroenterology, interventional radiology, and surgery. The work is also pertinent to practitioners in general medicine, public health, epidemiology, and family medicine, as well as medical students, trainees, and specialized nursing professionals.
This publication aligns with UN Sustainable Development Goal 3, which advocates for Good Health and Well-Being
